Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Long Term Strategy?

Any way you slice it, the shares are undervalued in my opinion by a factor of 4 - 6, minimally. If you take the value of our share of the MMP and discount the future cash flows we should currently have a market cap of at least $550,000,000 ($1.40 / share).

It is incumbent upon the BoD to eliminate the complete disconnect between the company's current market capitalization and the intrinsic value of our most precious asset, our share of the MMP. Perhaps it means monetizing the asset (for nothing less than $550mm), but no matter what, they need to get the tremendous value of the MMP asset to be reflected in the share price.

Perhaps the BoD is awating USPTO validation, but something tells me that at least 3 of them are incapable of getting this most important job done regardless of that matter. And if they can't do it, they should step aside in deference to others who are experienced in extracting value from assets.

Best

Share
New Message
Please login to post a reply